Solos Endoscopy, Inc. Board of Directors Authorizes Reorganization of Operating Divisions
Published: Mar 15, 2007
Within the last year, Solos Endoscopy has seen its business expand into numerous growing endoscopic markets, ranging from its emergence into the breast endoscopy market for early detection of breast cancer, into the endoscopic veterinary market and continued growth within the $20 billion general endoscopic (laparoscopic) marketplace.
"As our market opportunities and product lines rapidly expand, we see an immediate need to bring in knowledgeable professionals to focus on and execute the Company's strategy for each operating division. This corporate structure will provide us with a more efficient operating platform in order to service our diverse customer base and our rapidly expanding worldwide market presence. The board of directors also feels that this reorganization, for numerous reasons, will translate into increased value for our shareholders," stated Bob Segersten, CEO and President of Solos Endoscopy, Inc.
Highlighted Links Solos Endoscopy, Inc.
Solos Endoscopy, Inc. recently reported that a number of successful sales leads were generated by representatives at the 24th Annual Miami Breast Cancer Conference. The Company will immediately begin following up with the doctors and medical facilities from around the world that showed interest in Solos Endoscopy's line of endoscopic products.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
To automatically receive instant updates, press releases, and other information on this and other Big Apple Consulting USA companies, please visit www.bigappleconsulting.com/compro.php and download your FREE copy of Big Apple ComPro.
Contact: Investor Relations for Solos Endoscopy, Inc. 1-866-THE-APPL(E) www.solosendoscopy.com
SOURCE: Solos Endoscopy, Inc.